Skip to main content
Top
Published in: BMC Public Health 1/2012

Open Access 01-12-2012 | Research article

Regional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland

Authors: Pedro Marques-Vidal, Fred Paccaud

Published in: BMC Public Health | Issue 1/2012

Login to get access

Abstract

Background

In Switzerland, health policies are decided at the local level, but little is known regarding their impact on the screening and management of cardiovascular risk factors (CVRFs). We thus aimed at assessing geographical levels of CVRFs in Switzerland.

Methods

Swiss Health Survey for 2007 (N = 17,879). Seven administrative regions were defined: West (Leman), West-Central (Mittelland), Zurich, South (Ticino), North-West, East and Central Switzerland. Obesity, smoking, hypertension, dyslipidemia and diabetes prevalence, treatment and screening within the last 12 months were assessed by interview.

Results

After multivariate adjustment for age, gender, educational level, marital status and Swiss citizenship, no significant differences were found between regions regarding prevalence of obesity or current smoking. Similarly, no differences were found regarding hypertension screening and prevalence. Two thirds of subjects who had been told they had high blood pressure were treated, the lowest treatment rates being found in East Switzerland: odds-ratio and [95% confidence interval] 0.65 [0.50-0.85]. Screening for hypercholesterolemia was more frequently reported in French (Leman) and Italian (Ticino) speaking regions. Four out of ten participants who had been told they had high cholesterol levels were treated and the lowest treatment rates were found in German-speaking regions. Screening for diabetes was higher in Ticino (1.24 [1.09 - 1.42]). Six out of ten participants who had been told they had diabetes were treated, the lowest treatment rates were found for German-speaking regions.

Conclusions

In Switzerland, cardiovascular risk factor screening and management differ between regions and these differences cannot be accounted for by differences in populations' characteristics. Management of most cardiovascular risk factors could be improved.
Appendix
Available only for authorised users
Literature
1.
go back to reference Levi F, Lucchini F, Negri E, La Vecchia C: Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002, 88: 119-124. 10.1136/heart.88.2.119.CrossRefPubMedPubMedCentral Levi F, Lucchini F, Negri E, La Vecchia C: Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002, 88: 119-124. 10.1136/heart.88.2.119.CrossRefPubMedPubMedCentral
2.
go back to reference Pickle LW, Gillum RF: Geographic variation in cardiovascular disease mortality in US blacks and whites. J Natl Med Assoc. 1999, 91: 545-556.PubMedPubMedCentral Pickle LW, Gillum RF: Geographic variation in cardiovascular disease mortality in US blacks and whites. J Natl Med Assoc. 1999, 91: 545-556.PubMedPubMedCentral
3.
go back to reference Jarvie JL, Johnson CE, Wang Y, Aslam F, Athanasopoulos LV, Pollin I, et al: Geographic variance of cardiovascular risk factors among community women: the national Sister to Sister campaign. J Womens Health (Larchmt). 2011, 20: 11-19. 10.1089/jwh.2010.2036.CrossRef Jarvie JL, Johnson CE, Wang Y, Aslam F, Athanasopoulos LV, Pollin I, et al: Geographic variance of cardiovascular risk factors among community women: the national Sister to Sister campaign. J Womens Health (Larchmt). 2011, 20: 11-19. 10.1089/jwh.2010.2036.CrossRef
4.
go back to reference Lawlor DA, Bedford C, Taylor M, Ebrahim S: Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health. 2003, 57: 134-140. 10.1136/jech.57.2.134.CrossRefPubMedPubMedCentral Lawlor DA, Bedford C, Taylor M, Ebrahim S: Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health. 2003, 57: 134-140. 10.1136/jech.57.2.134.CrossRefPubMedPubMedCentral
5.
go back to reference Lei S, Yong-Yong X, Xiao-Han D, Chang-Sheng C: Geographical differences in blood pressure of male youth aged 17-21 years in China. Blood Press. 2004, 13: 169-175. 10.1080/08037050410035545.CrossRefPubMed Lei S, Yong-Yong X, Xiao-Han D, Chang-Sheng C: Geographical differences in blood pressure of male youth aged 17-21 years in China. Blood Press. 2004, 13: 169-175. 10.1080/08037050410035545.CrossRefPubMed
6.
go back to reference Chow CM, Donovan L, Manuel D, Johansen H, Tu JV: Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol. 2005, 21: 1265-1271.PubMed Chow CM, Donovan L, Manuel D, Johansen H, Tu JV: Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol. 2005, 21: 1265-1271.PubMed
7.
go back to reference Soljak M, Samarasundera E, Indulkar T, Walford H, Majeed A: Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis. BMC Cardiovasc Disord. 2011, 11: 12-10.1186/1471-2261-11-12.CrossRefPubMedPubMedCentral Soljak M, Samarasundera E, Indulkar T, Walford H, Majeed A: Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis. BMC Cardiovasc Disord. 2011, 11: 12-10.1186/1471-2261-11-12.CrossRefPubMedPubMedCentral
8.
go back to reference Marques-Vidal P, Arveiler D, Evans A, Amouyel P, Ferrières J, Luc G, et al: Awareness, treatment and control of hyperlipidaemia in middle-aged men in France and Northern Ireland in 1991-1993: the PRIME study. Prospective epidemiological study of myocardial infarction. Acta Cardiol. 2002, 57: 117-123. 10.2143/AC.57.2.2005383.CrossRefPubMed Marques-Vidal P, Arveiler D, Evans A, Amouyel P, Ferrières J, Luc G, et al: Awareness, treatment and control of hyperlipidaemia in middle-aged men in France and Northern Ireland in 1991-1993: the PRIME study. Prospective epidemiological study of myocardial infarction. Acta Cardiol. 2002, 57: 117-123. 10.2143/AC.57.2.2005383.CrossRefPubMed
9.
go back to reference Pardell H, Roure E, Drygas W, Morava E, Nussel E, Puska P, et al: East-west differences in reported preventive practices. A comparative study of six European areas of the WHO-CINDI programme. Eur J Public Health. 2001, 11: 393-396. 10.1093/eurpub/11.4.393.CrossRefPubMed Pardell H, Roure E, Drygas W, Morava E, Nussel E, Puska P, et al: East-west differences in reported preventive practices. A comparative study of six European areas of the WHO-CINDI programme. Eur J Public Health. 2001, 11: 393-396. 10.1093/eurpub/11.4.393.CrossRefPubMed
10.
go back to reference Marrugat J, Senti M: Why mortality from heart disease is low in France. High cholesterol may not have same effect on cardiovascular risk in southern Europe as elsewhere. BMJ. 2000, 320: 250-10.1136/bmj.320.7229.250.CrossRefPubMed Marrugat J, Senti M: Why mortality from heart disease is low in France. High cholesterol may not have same effect on cardiovascular risk in southern Europe as elsewhere. BMJ. 2000, 320: 250-10.1136/bmj.320.7229.250.CrossRefPubMed
11.
go back to reference Reich O, Weins C, Schusterschitz C, Thoni M: Exploring the disparities of regional health care expenditures in Switzerland: some empirical evidence. Eur J Health Econ. 2011, Reich O, Weins C, Schusterschitz C, Thoni M: Exploring the disparities of regional health care expenditures in Switzerland: some empirical evidence. Eur J Health Econ. 2011,
12.
go back to reference Etat de la prévention du tabagisme dans les cantons [Status of smoking prevention among cantons]. Office Fédéral de la Santé Publique [Federal Office of Public Health]. 2011 Etat de la prévention du tabagisme dans les cantons [Status of smoking prevention among cantons]. Office Fédéral de la Santé Publique [Federal Office of Public Health]. 2011
13.
go back to reference Cheng CL, Chen YC, Liu TM, Yang YH: Using spatial analysis to demonstrate the heterogeneity of the cardiovascular drug-prescribing pattern in Taiwan. BMC Publ Health. 2011, 11: 380-10.1186/1471-2458-11-380.CrossRef Cheng CL, Chen YC, Liu TM, Yang YH: Using spatial analysis to demonstrate the heterogeneity of the cardiovascular drug-prescribing pattern in Taiwan. BMC Publ Health. 2011, 11: 380-10.1186/1471-2458-11-380.CrossRef
14.
go back to reference Gerber PA, Spirk D, Brandle M, Thoenes M, Lehmann R, Keller U: Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. Swiss Med Wkly. 2011, 141: w13218-PubMed Gerber PA, Spirk D, Brandle M, Thoenes M, Lehmann R, Keller U: Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. Swiss Med Wkly. 2011, 141: w13218-PubMed
15.
go back to reference Schweizerische Gesundheitsbefragung: Gesundheit und Gesundheitsverhalten in der Schweiz 1997 [Swiss Health Survey: Health behavior and health in Switzerland 1997]. 2000, Neuchâtel, Swtzerland: Bundesamt für Statistik [Federal Office of Statistics] Schweizerische Gesundheitsbefragung: Gesundheit und Gesundheitsverhalten in der Schweiz 1997 [Swiss Health Survey: Health behavior and health in Switzerland 1997]. 2000, Neuchâtel, Swtzerland: Bundesamt für Statistik [Federal Office of Statistics]
16.
go back to reference IHA-GfK: Schweizerische Gesundheitsbefragung SGB 2002--Schlussbericht zur Datenerhebung [Swiss Health Survey 2002--Final Report on Data Collection]. 2003, Neuchâtel, Switzerland: Bundesamt für Statistik [Federal Office of Statistics] IHA-GfK: Schweizerische Gesundheitsbefragung SGB 2002--Schlussbericht zur Datenerhebung [Swiss Health Survey 2002--Final Report on Data Collection]. 2003, Neuchâtel, Switzerland: Bundesamt für Statistik [Federal Office of Statistics]
17.
go back to reference Faeh D, Bopp M: Excess weight in the canton of Zurich, 1992-2009: harbinger of a trend reversal in Switzerland?. Swiss Med Wkly. 2010, 140: w13090-PubMed Faeh D, Bopp M: Excess weight in the canton of Zurich, 1992-2009: harbinger of a trend reversal in Switzerland?. Swiss Med Wkly. 2010, 140: w13090-PubMed
18.
go back to reference Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pécoud A, et al: Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil. 2009, 16: 66-72. 10.1097/HJR.0b013e32831e9511.CrossRefPubMed Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pécoud A, et al: Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil. 2009, 16: 66-72. 10.1097/HJR.0b013e32831e9511.CrossRefPubMed
19.
go back to reference Ward PR, Noyce PR, Leger St: Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health. 2004, 58: 89-96. 10.1136/jech.58.2.89.CrossRefPubMedPubMedCentral Ward PR, Noyce PR, Leger St: Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health. 2004, 58: 89-96. 10.1136/jech.58.2.89.CrossRefPubMedPubMedCentral
20.
go back to reference Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, et al: Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. Eur J Cardiovasc Prev Rehabil. 2010, 17: 682-687. 10.1097/HJR.0b013e32833a09ab.CrossRefPubMed Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, et al: Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. Eur J Cardiovasc Prev Rehabil. 2010, 17: 682-687. 10.1097/HJR.0b013e32833a09ab.CrossRefPubMed
21.
go back to reference Nanchen D, Chiolero A, Marques-Vidal PM, Cornuz J, Waeber G, Vollenweider P, et al: Prescription de statines en prevention primaire: quel score de risque cardiovasculaire faut-il utiliser en Suisse? [Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?]. Rev Med Suisse. 2010, 6: 488-493.PubMed Nanchen D, Chiolero A, Marques-Vidal PM, Cornuz J, Waeber G, Vollenweider P, et al: Prescription de statines en prevention primaire: quel score de risque cardiovasculaire faut-il utiliser en Suisse? [Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?]. Rev Med Suisse. 2010, 6: 488-493.PubMed
22.
go back to reference Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011, 32: 1769-1818.CrossRefPubMed Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011, 32: 1769-1818.CrossRefPubMed
23.
go back to reference Marques-Vidal P, Rodondi N, Bochud M, Pécoud A, Hayoz D, Paccaud F, et al: Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. Eur J Cardiovasc Prev Rehabil. 2008, 15: 402-408. 10.1097/HJR.0b013e3282fb040f.CrossRefPubMed Marques-Vidal P, Rodondi N, Bochud M, Pécoud A, Hayoz D, Paccaud F, et al: Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. Eur J Cardiovasc Prev Rehabil. 2008, 15: 402-408. 10.1097/HJR.0b013e3282fb040f.CrossRefPubMed
24.
go back to reference Ito MK, Nanchen D, Rodondi N, Paccaud F, Waeber G, Vollenweider P, et al: Statins for cardiovascular prevention according to different strategies: a cost analysis. Am J Cardiovasc Drugs. 2011, 11: 33-44. 10.2165/11586760-000000000-00000.CrossRefPubMed Ito MK, Nanchen D, Rodondi N, Paccaud F, Waeber G, Vollenweider P, et al: Statins for cardiovascular prevention according to different strategies: a cost analysis. Am J Cardiovasc Drugs. 2011, 11: 33-44. 10.2165/11586760-000000000-00000.CrossRefPubMed
25.
go back to reference Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P: Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med. 2012, 29 (2): 190-7.CrossRefPubMed Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P: Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med. 2012, 29 (2): 190-7.CrossRefPubMed
26.
go back to reference American Diabetes Association: Screening for type 2 diabetes. Diabetes Care. 2004, 27 (Suppl 1): S11-S14. American Diabetes Association: Screening for type 2 diabetes. Diabetes Care. 2004, 27 (Suppl 1): S11-S14.
27.
go back to reference American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008, 31 (Suppl 1): S55-S60.CrossRef American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008, 31 (Suppl 1): S55-S60.CrossRef
28.
go back to reference Dyson PA, Kelly T, Deakin T, Duncan A, Frost G, Harrison Z, et al: Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med. 2011, 28: 1282-1288. 10.1111/j.1464-5491.2011.03371.x.CrossRefPubMed Dyson PA, Kelly T, Deakin T, Duncan A, Frost G, Harrison Z, et al: Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med. 2011, 28: 1282-1288. 10.1111/j.1464-5491.2011.03371.x.CrossRefPubMed
29.
go back to reference World Health Organization: WHO/NMH/MNC/03. Screening for type 2 diabetes. Edited by: Department of Noncommunicable Disease Management. 2003, Geneva, Switzerland: World Health Organization, 1-54. World Health Organization: WHO/NMH/MNC/03. Screening for type 2 diabetes. Edited by: Department of Noncommunicable Disease Management. 2003, Geneva, Switzerland: World Health Organization, 1-54.
30.
go back to reference OECD, WHO: OECD Reviews of Health Systems: Switzerland 2011. 2011, Paris, France: OECD Publishing OECD, WHO: OECD Reviews of Health Systems: Switzerland 2011. 2011, Paris, France: OECD Publishing
31.
go back to reference Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pecoud A, Hayoz D, et al: Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. Int J Cardiol. 2009, 133: 346-353. 10.1016/j.ijcard.2008.01.004.CrossRefPubMed Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pecoud A, Hayoz D, et al: Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. Int J Cardiol. 2009, 133: 346-353. 10.1016/j.ijcard.2008.01.004.CrossRefPubMed
32.
go back to reference Kotseva K, Wood D, De Backer G, de Bacquer D, Pyörälä K, Reiner Z, et al: EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010, 17: 530-540. 10.1097/HJR.0b013e3283383f30.CrossRefPubMed Kotseva K, Wood D, De Backer G, de Bacquer D, Pyörälä K, Reiner Z, et al: EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010, 17: 530-540. 10.1097/HJR.0b013e3283383f30.CrossRefPubMed
33.
go back to reference Faeh D, Marques-Vidal P, Chiolero A, Bopp M: Obesity in Switzerland: do estimates depend on how body mass index has been assessed?. Swiss Med Wkly. 2008, 138: 204-210.PubMed Faeh D, Marques-Vidal P, Chiolero A, Bopp M: Obesity in Switzerland: do estimates depend on how body mass index has been assessed?. Swiss Med Wkly. 2008, 138: 204-210.PubMed
34.
go back to reference Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al: Recommendations for organizing a standardized European Health Examination Survey. 22/2008, 1-13. 2008, Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute] Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al: Recommendations for organizing a standardized European Health Examination Survey. 22/2008, 1-13. 2008, Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute]
35.
go back to reference Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al: Recommendations for the Health Examination Surveys in Europe. 21/2008, 1-181. 2008, Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute] Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al: Recommendations for the Health Examination Surveys in Europe. 21/2008, 1-181. 2008, Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute]
36.
go back to reference Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al: Review of Health Examination Surveys in Europe. 18/2008. 2008, Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute] Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al: Review of Health Examination Surveys in Europe. 18/2008. 2008, Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute]
Metadata
Title
Regional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland
Authors
Pedro Marques-Vidal
Fred Paccaud
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2012
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-12-246

Other articles of this Issue 1/2012

BMC Public Health 1/2012 Go to the issue